Early Initiation of Emicizumab Prophylaxis in Infants With Severe Hemophilia A, a Real-World Experience

BACKGROUND: Intracranial hemorrhage (ICH) is common in infants with hemophilia. We evaluated 15 children with severe hemophilia A who were initiated on emicizumab prophylaxis in infancy at the Pediatric Coagulation Center in Dublin, Ireland. OBSERVATIONS: The median age at emicizumab initiation was 13 weeks (range, 1 to 38 wk), and in 9 children diagnosed in the first week of life, it was 5 weeks (range, 1 to 16 wk). After a median follow-up of 36.3 months (15.6 to 55.75), no child developed ICH or spontaneous bleeding. CONCLUSIONS: Emicizumab prophylaxis in early infancy is safe and effective in the prevention of ICH and spontaneous bleeding in children with severe hemophilia A.

Authors

Institutions

Publication Details

Journal
Journal of Pediatric Hematology/Oncology
Published
2026-11-18
DOI
https://doi.org/10.1097/mph.0000000000003322
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Early Initiation of Emicizumab Prophylaxis in Infants With Severe Hemophilia A, a Real-World Experience

Beatrice Nolan, Saad Ahmed
2 links
Journal of Pediatric Hematology/Oncology
Hemophilia Treatment and Research
article

Early Initiation of Emicizumab Prophylaxis in Infants With Severe Hemophilia A, a Real-World Experience

Beatrice Nolan, Saad Ahmed
article en

Abstract

BACKGROUND: Intracranial hemorrhage (ICH) is common in infants with hemophilia. We evaluated 15 children with severe hemophilia A who were initiated on emicizumab prophylaxis in infancy at the Pediatric Coagulation Center in Dublin, Ireland. OBSERVATIONS: The median age at emicizumab initiation was 13 weeks (range, 1 to 38 wk), and in 9 children diagnosed in the first week of life, it was 5 weeks (range, 1 to 16 wk). After a median follow-up of 36.3 months (15.6 to 55.75), no child developed ICH or spontaneous bleeding. CONCLUSIONS: Emicizumab prophylaxis in early infancy is safe and effective in the prevention of ICH and spontaneous bleeding in children with severe hemophilia A.

Journal of Pediatric Hematology/Oncology
University College Dublin (IE), Trinity College (CA), Trinity College Dublin (IE), Children's Health Ireland at Crumlin (IE)
Good health and well-being
Hemophilia Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon